Find Clinical Trials & Research Studies

NORD shares information about opportunities to participate in clinical trials and other studies so that patients and their physicians may decide whether specific studies are appropriate for them. We do not endorse or recommend participation in any specific clinical trials or studies. The following is a brief sampling of current clinical trials listed at www.clinicaltrials.gov.


Current Clinical Trials & Studies

15q Duplication Syndrome

Ovid Therapeutics Inc. is sponsoring a study to investigate the effect of TAK-935 on the frequency of motor seizures in patients with 15q duplication syndrome during the maintenance period.

More
Achondroplasia (ACH) 

Ascendis Pharma, Inc. is sponsoring a natural history study to examine height velocity and comorbidities in children with ACH.

More

Ascendis Pharma, Inc. Is sponsoring a multicenter, double-blind, randomized, placebo-controlled, dose escalation trial evaluating the safety, efficacy, and pharmacokinetics of TransCon CNP administered once weekly in prepubertal children with ACH.

More
Achromatopsia CNGB3

AGTC is currently conducting a clinical study to evaluate the safety and efficacy of an investigational gene therapy in patients with achromatopsia caused by mutations in the CNGB3 gene. If you are eligible to join the study and choose to participate, all study-related treatment costs and medical testing will be provided at no charge. Compensation for your time and travel expenses may also be provided.

More
Acromegaly

Ionis Pharmaceuticals is investigating the safety, tolerability, and efficacy of IONIS-GHR-LRx in up to 42 adult patients with acromegaly being treated with long-acting somatostatin receptor ligands. Clinicaltrials.gov-NCT03548415.

Clinicaltrials.gov-NCT03548415

Ionis Pharmaceuticals, Inc. is conducting a short-term study to assess changes in serum insulin-like growth factor 1 (IGF-1) over a 16-week treatment period in patients with acromegaly being treated with long-acting somatostatin receptor ligands (SRL). Clinicaltrials.gov-NCT03548415

Clinicaltrials.gov-NCT03548415

Camurus AB is investigating the efficacy and safety of octreotide subcutaneous depot (CAM2029) in a 24-week randomized trial in 78 patients with acromegaly and who are on treatment with long-acting somatostatin analogues (ClinicalTrials.gov Identifier: NCT04076462).

NCT04076462

Camurus AB is conducting a 52-week open-label trial to assess the long-term safety of octreotide subcutaneous depot (CAM2029) in 140 patients with acromegaly and who are on treatment with long-acting somatostatin analogues (ClinicalTrials.gov Identifier: NCT04125836).

NCT04125836
Acute Myeloid Leukemia

Astellas Pharma Global Development, Inc. is sponsoring a phase 1 and phase 2 study of gilteritinib in combination with chemotherapy in children, adolescents and young adults with FMS-like tyrosine kinase 3 (FLT3)/internal tandem duplication (ITD) positive relapsed or refractory AML. Estimated enrollment is 97 participants. More.

More

Rubius Therapeutics is sponsoring a phase 1, open label, multicenter, multidose, first-in-human (FIH) dose escalation and expansion to determine the safety and tolerability, pharmacology, and antitumor activity of RTX-240 in adult patients with relapsed/refractory acute myeloid leukemia. More.

More

Lynk Pharmaceuticals is sponsoring a multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with AML. More.

More
Advanced Solid Tumors

Exicure, Inc. is sponsoring a phase 1b study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral cavrotolimod injections alone and in combination with intravenous pembrolizumab or cemiplimab in patients with advanced solid tumors. A phase 2 study will evaluate cavrotolimod given in combination with pembrolizumab or cemiplimab in patients with Merkel cell carcinoma and cutaneous squamous cell carcinoma. More.

More

Rubius Therapeutics is sponsoring a phase 1/2, open label, multicenter, multidose, first-in-human (FIH) dose escalation and expansion to determine the safety and tolerability, recommended phase 2 dose and optimal dosing interval, pharmacology, and antitumor activity of RTX-240 in adult patients with relapsed/refractory or locally advanced solid tumors. More.

More
Allergic Bronchopulmonary Aspergillosis

Regeneron Pharmaceuticals is sponsoring a study in collaboration with Sanofi to evaluate the efficacy of dupilumab on the annualized rate of exacerbations in patients with allergic bronchopulmonary aspergillosis. Estimated enrollment is 170 participants. More.

More
Alpha-1 Antitrypsin Deficiency (A1ATD)-Associated Liver Disease

Dicerna Pharmaceuticals, Inc. is sponsoring a study to test the experimental drug DCR-A1AT to see if it helps people with AIATD-associated liver disease.

More
Alpha-1 Proteinase Inhibitor (A1PI) Deficiency and Chronic Pulmonary Disease (COPD)

A study is enrolling adults diagnosed with A1PI deficiency and COPD. This study will evaluate the weekly administration of A1PI augmentation therapy in patients with A1PI and COPD. For more information, visit: ClinicalTrials.gov –  NCT02722304

ClinicalTrials.gov –  NCT02722304
Alport Syndrome

Sanofi Genzyme is conducting a phase II, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, pharmacodynamics, and pharmacokinetics of SAR339375 in patients with Alport syndrome.

More
Amyloidosis

Caelum Biosciences, Inc. is sponsoring a study to determine the recommended dose of CAEL-101, to facilitate progression of further clinical trials, and evaluate safety and tolerability of CAEL-101 in combination with the standard of care (cyclophosphamide-bortezomib-dexamethasone (CyBorD) chemotherapy and daratumumab) in patients with AL Amyloidosis.

More

Caelum Biosciences, Inc. is sponsoring a study to evaluate the effectiveness and safety of CAEL-101 in patients with Mayo Stage IIIa AL Amyloidosis.

More

Caelum Biosciences, Inc. is sponsoring a study to evaluate the effectiveness and safety of CAEL-101 in patients with Mayo Stage IIIb Amyloidosis.

More

Alnylam Pharmaceuticals is sponsoring a study to evaluate the efficacy and safety of patisiran in patients with ATTR amyloidosis with cardiomyopathy.

More

Alnylam Pharmaceuticals is sponsoring a study to evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously once every 3 months compared to placebo in patients with ATTR amyloidosis with cardiomyopathy.

More

Alnylam Pharmaceuticals is sponsoring a global observational study to describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients; characterize the safety and effectiveness of patisiran as part of routine clinical practice in the real-world clinical setting; and describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) mutation.

More

Prothena Biosciences Ltd is sponsoring a phase 3, multicenter, global, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of birtamimab in treating Mayo Stage IV patients with AL amyloidosis.

Amyotrophic Lateral Sclerosis (ALS)

Alexion Pharmaceuticals is sponsoring a study to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.

More

Apellis Pharmaceuticals, Inc. is sponsoring a 24-month (including open label), phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in patients with ALS.

More

Biogen is sponsoring a study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) gene variant with elevated neurofilament. Secondary objectives are to evaluate the safety, tolerability and effect of tofersen on pharmacodynamics and treatment response biomarkers when initiated prior to versus at the time of emergence of symptoms of ALS.

More

Helixmith Co., Ltd. is sponsoring a phase 2 study to evaluate the safety of intramuscular (IM) administration of Engensis in patients with ALS as compared to placebo.

More

Ionis Pharmaceuticals, Inc. is sponsoring a phase 3, randomized study to evaluate the safety, efficacy, and pharmacodynamics of intrathecally administered ION363 in treating ALS patients with fused in sarcoma mutations.

More

PTC Therapeutics is sponsoring a study to assess the effects and safety of PTC857 to treat patients with ALS

More
Angelman Syndrome

Ionis Pharmaceuticals, Inc. is sponsoring a phase 1-2a, open-label study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecally administered ION582 in treating patients with Angelman syndrome.

More

Ovid Therapeutics Inc. is sponsoring a study to assess the efficacy and safety of oral OV101 (gaboxadol) in pediatric patients with Angelman syndrome.

More
Aplastic Anemia

Regeneron Pharmaceuticals is sponsoring a study to assess the safety and tolerability of REGN7257 in patients with severe aplastic anemia that is refractory to or has relapsed while on standard of care immunosuppressive therapy (IST) and to evaluate the clinical efficacy of REGN7257 in IST-refractory/relapsed patients.

More
Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics is sponsoring a multi-center randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of pegzilarginase in patients with ARG1-D.

More
Arrhythmogenic Cardiomyopathy

Rocket Pharmaceuticals Inc. is sponsoring a phase 1 dose escalation trial to evaluate the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with arrhythmogenic cardiomyopathy who have pathogenic PKP2 gene variants.

More
Atypical Hemolytic Uremic Syndrome (aHUS)

Genentech, Inc. is conducting a phase 3 single-arm study to evaluate the efficacy and safety of crovalimab in adult and adolescent patients with aHUS.

More

Genentech, Inc. is conducting a phase 3 single-arm study to evaluate the efficacy and safety of crovalimab in pediatric patients with aHUS.

More
Autoimmune Hemolytic Anemia (AIHA)

Rigel Pharmaceuticals is conducting a phase 3 study to assess the efficacy of fostamatinib in patients with warm antibody AIHA. For more information, visit:

ClinicalTrials:gov:NCT03764618
Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara, Inc. is sponsoring an interventional, randomized, double-blind, 2-arm, parallel groups, placebo-controlled, multi-center, phase 3 trial of once daily treatment with inhaled molgramostim or placebo for 48 weeks in adult patients with aPAP.

More

Savara, Inc. is sponsoring a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of molgramostim in adult patients with aPAP.

More
B-Cell Malignancies

Beigene is sponsoring a dose-escalation and expansion study of the bruton tyrosine kinase targeted protein degrader BGB-16673 in patients with B-cell malignancies including marginal zone lymphoma, follicular lymphoma, non-Hodgkin lymphoma, Waldenström’s macroglobulinemia, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma.

More

Ono Pharmaceutical Co. Ltd is sponsoring a first-in-human clinical study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of ONO-7018 in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia.

More
Batten Disease

Neurogene, Inc. is sponsoring a phase 1/2 interventional, prospective, non-randomized, first in human (FIH), open-label study of a single dose administration of gene therapy in children who are 3 to 8 years old with neuronal ceroid lipofuscinosis (Batten) subtype 5 (CLN5) disease. Efficacy assessments in this study will evaluate motor, language, visual and cognitive function and each participant will be followed for safety and efficacy for 5 years after treatment.

More

Neurogene, Inc. is sponsoring a study to investigate the clinical characteristics and natural clinical progression of symptoms in patients with the CLN5 and CLN7 forms of Batten disease. This natural history study is being conducted to better understand disease course and to determine clinically relevant outcome measures for use in future clinical trials.

More
Biliary Tract Cancers

Compass Therapeutics is sponsoring a multi-center, open-label, randomized, phase 2/3, controlled study to assess the efficacy of CTX-009 in combination with paclitaxel versus paclitaxel alone in adult patients with unresectable advanced, metastatic, or recurrent biliary tract cancers who have received one prior systemic chemotherapy regimen.

Learn More
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

ImmunoGen, Inc. is sponsoring an open-label, multi-center, phase 1/2 study to determine the maximum tolerated dose and assess the safety, tolerability, pharmacokinetics, immunogenicity, and anti-leukemia activity of IMGN632 when administered as monotherapy to patients with CD123+ disease. The study is enrolling a pivotal cohort of frontline BPDCN patients and a cohort of relapsed/refractory BPDCN patients.

More
Bullous Pemphigoid

AstraZeneca is sponsoring a multinational, randomized, double-blind study to evaluate the safety and efficacy of benralizumab in treating patients with bullous pemphigoid

More

Regeneron Pharmaceuticals and Sanofi are conducting a study to evaluate the efficacy and safety of dupilumab in adult patients with bullous pemphigoid.

More

Argenx is sponsoring a randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of efgartigimod PH20 SC in adult patients with bullous pemphigoid.

More

Argenx is sponsoring a phase 3, open-label extension study to evaluate the long-term safety, tolerability and efficacy of efgartigimod PH20 SC in adult patients with bullous pemphigoid.

More
C3 Glomerulopathy (C3G)

Achillion Pharmaceuticals is investigating the safety and efficacy of ACH-4471, an orally administered complement factor D inhibitor, in patients with C3 Glomerulopathy (C3G), including Dense Deposit Disease (DDD) and C3 Glomerulonephritis (C3GN). Two clinical studies are being conducted in multiple countries. For more information about these studies, please visit ClinicalTrials.gov: NCT03369236 and ClinicalTrials.gov: NCT03124368.

ClinicalTrials.gov: NCT03369236

ChemoCentryx is conducting a study to evaluate the effect of avacopan treatment on renal disease activity in patients with C3G.

More

Apellis Pharmaceuticals, Inc. is sponsoring a phase 2, multicenter, open-label, randomized, controlled study designed to evaluate the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of C3G.

More

Apellis Pharmaceuticals, Inc. is sponsoring a phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy based on a reduction in proteinuria. The anticipated enrollment is up to 90 participants.

More
Canavan Disease

Aspa Therapeutics is sponsoring a study to evaluate the safety, tolerability and pharmacodynamic activity of BBP-812, an investigational AAV9-based gene therapy, in pediatric patients with Canavan disease. The estimated enrollment for this study is 18 participants.

More
Cardiomyopathy

Tenaya Therapeutics is conducting a prospective and retrospective registry and biomarker study to collect information on the natural history of pediatric patients with cardiomyopathy due to mutations in the MYBPC3 gene.

More
CDKL5 Deficiency Disorder

Zogenix, Inc. is sponsoring a multicenter, double-blind, parallel-group, placebo controlled, 2-part study to evaluate the safety and efficacy of ZX008 when used as adjunctive therapy for the treatment of uncontrolled seizures in children and adults with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD).

More

Ovid Therapeutics Inc. is sponsoring a study to investigate the effect of TAK-935 on the frequency of motor seizures in patients with CDKL5 deficiency disorder during the maintenance period.

More
Cerebral Cavernous Malformation (CCM)

Recursion Pharmaceuticals Inc. is sponsoring a phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy, and pharmacokinetics of REC-994 compared to placebo for the treatment of patients with symptomatic CCM.

More
Cerebrotendinous Xanthomatosis (CTX)

Travere Therapeutics, Inc. is sponsoring an observational, multicenter study to determine the prevalence of CTX in patients diagnosed with early-onset idiopathic bilateral cataracts.

More
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Janssen Research & Development, LLC is sponsoring a multistage, multicenter, randomized, double-blind study to evaluate the safety and efficacy of nipocalimab in delaying relapse in adults with CIDP.

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Actelion Pharmaceuticals is sponsoring a study to assess the efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH.

More

Actelion Pharmaceuticals is sponsoring a study to evaluate the effect of macitentan 75 mg versus placebo on exercise capacity at week 28 in patients with CTEPH.

More
Cold Agglutinin Disease (CAD)

Swedish Orphan Biovitrum is sponsoring a phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the safety and efficacy of pegcetacoplan in increasing hemoglobin levels from baseline in patients with CAD in order to avoid transfusion.

Congenital Adrenal Hyperplasia (CAH)

Neurocrine Biosciences is sponsoring a phase 3 study to evaluate the efficacy, safety and tolerability of crinecerfont versus placebo administered for 24 weeks in adult patients with classic CAH due to 21-hydroxylase deficiency.

More

Adrenas Therapeutics, Inc. is sponsoring a study to evaluate the safety, tolerability and efficacy of AAV5 based BBP-631 in adult patients with classic congenital adrenal hyperplasia.

More
Congenital Myasthenic Syndromes

Catalyst Pharmaceuticals, Inc. is sponsoring a randomized, double-blind, controlled, outpatient two-period, two-treatment crossover study is designed to evaluate the efficacy and safety of amifampridine phosphate in patients (ages 2 to 70) diagnosed with certain genetic subtypes of CMS and demonstrated open label (amifampridine phosphate) or history of sustained amifampridine benefit from treatment.For more information visit ClinicalTrials.gov: NCT02562066

ClinicalTrials.gov: NCT02562066
Congenital Sucrase-Isomaltase Deficiency (CSID)

QOL Medical, LLC is sponsoring an open-label, phase 4, multi-center study to evaluate the use of a 7-day therapeutic trial dose of sarcrosidase (Sucraid) in alleviating CSID symptoms in pediatric patients with low, moderate and normal sucrase levels.

Creatine Deficiency

Researchers at the University of British Columbia are conducting a survey to collect data about behavior following treatment for creatine deficiency syndrome (CDS). Questions for patients and their parents or caregivers pertain to diagnostic history, presenting symptoms during life span, and response to treatments with focus on patient and caregiver reported observations.

More
Cystic Fibrosis

The University of Maryland School of Medicine is conducting a study to evaluate the process that Latine-identifying caregivers of children with cystic fibrosis have gone through to access genetic testing and/or genetic counseling services. Participation involves an anonymous online survey that will take approximately 15 minutes to complete and is available in English and Spanish.

Cytomegalovirus (CMV) Infection

ModernaTX, Inc. is sponsoring a study to evaluate the efficacy of mRNA 1647 vaccine in healthy CMV-seronegative female participants and the safety and reactogenicity of mRNA-1647 vaccine in all healthy participants. Estimated enrollment is 6900 participants.

 

More

ModernaTX, Inc. is sponsoring a study to evaluate the safety, reactogenicity and immunogenicity of the mRNA-1647 vaccine administered according to a 3-study injection schedule in healthy cytomegalovirus-seronegative and cytomegalovirus-seropositive Japanese adults 18 to 40 years of age in the United States. Estimated enrollment is 48 participants.

More

Shire is sponsoring study is to compare the efficacy and safety of maribavir to valganciclovir for the treatment of CMV infection in asymptomatic hematopoietic stem  cell transplant recipients. For more information visit:

More

Shire is sponsoring a study is to determine if an investigational treatment (Maribavir) is safe and effective in treating transplant recipient subjects with CMV infections that are refractory or resistant to treatment with ganciclovir, valganciclovir, foscarnet, or cidofovir. For more information visit:

More
Danon Disease

Rocket Pharmaceuticals Inc. is sponsoring a non-randomized open-label phase 1 study to evaluate the safety and toxicity of gene therapy using a recombinant adeno-associated virus serotype 9 (AAV9) containing the human lysosome-associated membrane protein 2 isoform B (LAMP2B) transgene (investigational product (IP), RP-A501) in male patients with Danon disease.

More

Rocket Pharmaceuticals Inc. is sponsoring a phase 2 gene therapy trial to evaluate the efficacy and safety of RP-A501 in male patients with Danon disease.

More

Rocket Pharmaceuticals Inc. is sponsoring an international observational study to learn about the natural history of Danon disease in male patients >8 years of age

More
Desmoid Tumor

SpringWorks Therapeutics, Inc. is offering an individual patient compassionate use program for nirogacestat for patients with desmoid tumor or NOTCH gene mutation positive tumors.

Discoid Lupus Erythematosus (DLE)

LEO Pharma is sponsoring a double-blind, multi-center, randomised, vehicle-controlled, within-subject trial designed to establish the efficacy and safety of delgocitinib cream in the treatment of adults with DLE.

More
Disorders of Puberty and Reproduction

Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) at the NIH are conducting two studies of people who have reproductive disorders. The studies will look into how genes and production of gonadotropin-releasing hormone affect puberty and infertility. Individuals 14 years of age and older with low testosterone or estrogen may be eligible. For more information visit

ClinicalTrials.gov: NCT01500447
Dravet Syndrome

Ovid Therapeutics Inc. is sponsoring a study is to investigate the effect on the frequency of all seizures (convulsive and drop) in patients with Dravet syndrome treated with TAK-935 compared to placebo.

More

Eisai Inc. is sponsoring a study to determine if lorcaserin has superior efficacy compared to placebo on percent change in frequency of convulsive seizures per 28 days in patients with Dravet syndrome.

More
Eosinophilic Esophagitis (EoE)

AstraZeneca Pharmaceuticals is sponsoring a phase 3 study is to investigate the use of benralizumab as a treatment for patients with EoE.

More

AstraZeneca is sponsoring a phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of tezepelumab in adult and adolescent patients with EoE.

More
Eosinophilic Granulomatosis With Polyangiitis (EGPA)

AstraZeneca Pharmaceuticals is sponsoring a randomized, double blind, active-controlled, parallel group, multicenter 52-week phase 3 study to compare the efficacy and safety of benralizumab 30 mg versus mepolizumab 300 mg administered by subcutaneous injection in patients with relapsing or refractory EGPA on corticosteroid therapy with or without stable immunosuppressive therapy.

More

GlaxoSmithKline is sponsoring a study to investigate the efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory EGPA.

More
Epileptic Encephalopathy with Continuous Spike-and-Wave During Sleep

Neurocrine Biosciences is sponsoring a phase 2, double-blind study to assess the efficacy, safety, tolerability and pharmacokinetics of NBI-827104 in pediatric patients with epileptic encephalopathy with continuous spike-and-wave during sleep (EECSWS).

More
Epstein-Barr Virus (EBV) Associated Diseases

Atara Biotherapeutics is sponsoring a study to evaluate tabelecleucel in patients with EBV-associated diseases.

More
Essential Thrombocythemia

PharmaEssentia is sponsoring a phase 2, single-arm, multicenter study to evaluate the safety, tolerability and efficacy of ropeginterferon alfa-2b-njft (P1101) in adult patients with essential thrombocythemia.

More
Familial Adenomatous Polyposis (FAP)

Recursion Pharmaceuticals Inc. is sponsoring a phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, efficacy and pharmacokinetics of REC-4481 in treating patients with FAP.

More